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1994-95 1996-97 1998-99 2000-01 2002-03 2004-05
N (%) N (%) N (%) N (%) N (%) N (%)
# of patients
Total 15,603 19,765 20,260 15,989 16,125 18,244
AutoHCT 10,557 (68) 13,628 (69) 13,931 (69) 9,602 (60) 9,449 (59) 10,918 (60)
AlloHCT 5,046 (32) 6,137 (31) 6,329 (31) 6,387 (40) 6,676 (41) 7,326 (40)
Median (range) Age, years
AutoHCT 44 (\1-75) 46 (\1-76) 48 (\1-78) 50 (\1-78) 52 (\1-91) 53(\1-81)
AlloHCT 33 (\1-68) 35 (\1-79) 37 (\1-76) 39 (\1-79) 40 (\1-76) 40 (\1-78)
AutoHCT graft source
Marrow 2,730 (26) 1,470 (11) 651 ( 5) 296 ( 3) 193 ( 2) 208 ( 2)
Blood 6,288 (60) 11,216 (82) 12,773 (92) 9,020 (94) 9,104 (96) 10,618 (97)
Marrow1 Blood 1,539 (15) 942 ( 7) 507 ( 4) 286 ( 3) 151 ( 2) 92 ( 1)
AlloHCT graft source
Marrow 4,571 (91) 4,693 (76) 4,420 (67) 2,834 (46) 2,111 (32) 1970 (27)
Peripheral Blood 357 ( 7) 1,129 (18) 1,640 (26) 2,996 (47) 3,912 (59) 4,588 (63)
Marrow1 Blood 33 ( 1) 36 ( 1) 45 ( 1) 26 (\1) 11 (\1) 27 (\1)
Cord Blood 85 ( 2) 279 ( 5) 404 ( 6) 531 ( 8) 642 (10) 741 (10)
AlloHCT donor relationship
HLA-identical Sibling 2,999 (59) 3,555 (58) 3,547 (56) 3,443 (54) 3,400 (51) 3,255 (44)
Unrelated 1,237 (25) 1,802 (29) 2,024 (32) 2,182 (34) 2.616 (39) 3,273 (45)
Other Relative 614 (12) 623 (10) 575 ( 9) 590 ( 9) 496 ( 7) 525 ( 7)
Other 25 ( 1) 18 (\1) 19 (\1) 61 ( 1) 87 ( 1) 160 ( 2)
Missing 171 ( 3) 139 ( 2) 164 ( 3) 111 ( 2) 77 ( 1) 113 ( 2)
Meta-analysis: CR and 2 yr OS post ASCTwith baseline lym-
phoma status
Poster Session I S199declined by .30% in the early 2000s, but rose again in 2004-5.
Most of this change is due to a decrease in AutoHCT for breast
cancer from 42% in 1994-5 to 1% in 2004-5. In this same period,
AutoHCT increased for MM (6% to 44%) and NHL/HL (33%
to 41%), whereas acute or chronic leukemia decreased from 8%
to 5% and solid tumors remained stable at 9%. The number of
AutoHCTs for the new indication of autoimmune diseases have
totaled 146 from 1996-2005. The number of AlloHCTs increased
by 45% over this 12-year period, mostly due to a 2.6-fold increase
in unrelated donor AlloHCTs. From 1994-5 to 2004-5, AlloHCT
increased for AML/ALL (43% to 51%), MDS/MPS (8% to 11%),
and NHL/HL (8% to 12%), but decreased for CML (23% to 8%)
and MM (5% to 1%). AlloHCT conditioning regimen intensity
was 100% myeloablative in 1994-5, whereas reduced intensity/
nonmyeloablative regimens were used in 28% of AlloHCTs in
2004-5. The use of peripheral blood and cord blood have dramat-
ically increased. The median age and upper age limit have in-
creased for both AutoHCT and AlloHCT. The percent of non-
White race recipients increased from 1994-5 to 2004-5 for both
autoHCT (8 to 17%) and AlloHCT (14 to 19%). In the entire
study period, there have been 2,115 planned tandem AutoHCTs,
242 planned tandem Auto/AlloHCTs, 48 planned tandem Allo/Al-
loHCTs, 1,135 unplanned Auto/AutoHCTs, 1,559 unplanned
Auto/AlloHCTs, 2,091 unplanned allo/AlloHCTs, and 2,828
other multiple HCTs (unknown if planned or unplanned). The
HCT population has changed dramatically over time. Further
analyses are ongoing to determine the impact of these changes
on the success of HCT.CR post
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR HIV-RELATED
LYMPHOMAS IN THE HAART ERA: A META-ANALYSIS OF RESPONSE AND
SURVIVAL POST TRANSPLANT
Sunil, M.1, Reid, E.G.2, Lechowicz, M.1 1Winship Cancer Institute
Emory University, Atlanta, GA; 2Moores Cancer Center University of
California San Diego, CA
Introduction: Recently data has shown survival and response rates
in small numbers of HIV patients receiving ASCT for HL andNHL in the HAART era. We did a comprehensive review and
meta-analysis of the literature to examine collective therapeutic out-
comes and survival.
Methods: We searched OVID, PUBMED, Google Scholar (1980 –
Sept 2009), ASH (2004-8), ASCO (2004-9), and BMT Tandem
(2005-9) annual meeting abstracts for references. Articles obtained
were reviewed for additional references. Inclusion criteria: 1) Autol-
ogous transplants for HIV/AIDS associated lymphoma with
HAART 2) Reported in English 3) Studies reporting: complete re-
sponse rates (CR), and one or more survival statistics. 4) Compre-
hensive trials, cohort studies or case series. Authors were queried
for possible patient overlap among studies. Primary outcome mea-
sures were response to ASCT and 2 year overall survival rates (OS).
Results: Out of 61 references, 14 studies were on ASCT in HIV
related lymphoma and 13 case reports. 5 met inclusion criteria.
These included 35 Hodgkins and 83 NHL subjects. CR rates
post ASCT 71% (95%CI 60-80), 2 year OS of 71% (95%CI
61-79) (see Table). Subjects entering ASCT in CR had a post
ASCT CR rate of 91%, and a 2 year OS rate of 70%. Compared
to subjects without CR when entering ASCT, those in CR at time
of ASCT were 8-fold more likely to be in CR post ASCT and 3-
fold likelihood of being alive at 2 years post ASCT. Difference in
survival were not apparent between transplantation in CR1, CR2,
or greater than CR2. Achievement of CR appears to be predictive
S200 Poster Session Iof 2-year survival. Summary data regarding histologic subtype,
stage, immune status, viral load at ASCT and conditioning regi-
men will also be presented.
Conclusion: ASCT for HIV(+) patients has a comparable response
and survival to the HIV(-) population for ASCT. Consideration of
ASCT as an earlier therapeutic option in HIV related lymphoma
should be investigated. Additional prospective trials are necessary
to determine optimal management of this population.115
DEFINING THE OPTIMAL THRESHOLD OF PERIPHERAL BLOOD (PB)
CD34 + CELLS TO INITIATE APHERESIS IN PATIENTS WITH NHL UNDER-
GOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
(AUTO-HSCT) AFTER G-CSF MOBILIZATION
DiPersio, J.1, Nademanee, A.2, Stiff, P.3, Stadtmauer, E.4, Mody, P.5,
Marulkar, S.5, Micallef, I.6 1Washington University School of Medicine,
St. Louis, MO; 2City of Hope National Medical Center, Duarte, CA;
3Loyola University, Maywood, IL; 4Abramson Cancer Center, University
of Pennsylvania, Philadelphia, PA; 5Genzyme Corporation, Cambridge,
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Introduction: PB CD34+ cells are routinely monitored to optimize
the timing and success of CD34+ stem cell collection after G-CSF6
chemotherapy mobilization in NHL patients (pts) undergoing auto-
HSCT. A threshold of#10 PB CD34+ cells/ml is often used to predict
poor mobilization and aid the decision of whether novel therapies
such as plerixafor should be included in the mobilization scheme.
This analysis evaluated whether a PB threshold#10 cells/ml is indeed
the most optimal threshold to predict mobilization failure.
Methods:This was a post-hoc analysis of pts with NHL (enrolled in
the phase 3 study 3101) mobilized with G-CSF alone (10 mg/kg SC
for up to 8 doses). PB CD34+ cells were measured on the morning of
Day 4,24H prior to apheresis. The proportion of pts collecting the
minimal ($2  106) or optimal ($5  106) CD34+ cell dose and
apheresis yields were evaluated in pts with PB CD34+ cells/ml #10
(PB #10) or .10 (PB .10).
Results: This analysis was restricted to patients randomized to re-
ceive G-CSF plus placebo. In the 3101 study, 142 pts were mobi-
lized with G-CSF alone; Day 4 PB CD34 cell counts were available
for 124 pts. 75/124 (60%) pts had PB #10 and 49/124 (40%) pts
had PB .10. The median CD34+ cell yield in 2 days was 0.97 
106 cells/kg in pts with PB #10 and 3.3  106 cells/kg in pts
with PB .10. The median CD34+ cell yield in 4 days was 1.31
 106 cells/kg in pts with PB #10 and 4.52  106 cells/kg in pts
with PB .10. Only 22.7% pts with PB #10 and 65.3% pts with
PB .10 collected the minimal cell dose of $2 x106 cells/kg in 2
days. If apheresis was continued for 4 days then 34.7% pts with
PB #10 and 79.6% pts with PB .10 were able to collect the min-
imal dose. Similarly, only 5.3% pts with PB #10 and 30.6% pts
with PB .10 collected the optimal cell dose of $5 x106 cells/kg
in 2 days. Continuing apheresis for 4 days allowed 10.7% patients
with PB #10 and 40.8% patients with PB .10 to collect the opti-
mal dose.
Conclusion: Collectively, these data demonstrate that if apheresis
was planned in pts with .10 PB CD34+ cells/ml, then 20.4% pts
would not collect the minimal cell dose ($2106) and 59.2% pts
would not collect the optimal cell dose ($5106) in 4 apheresis
days. Thus, a threshold of .10 PB CD34+ cells/ml does not en-
sure adequate stem cell collection in a significant proportion of
NHL patients mobilized with G-CSF alone. Higher PB
CD34+ thresholds should be evaluated to ensure effective HSC
collection in NHL pts proceeding to HSCT.
Mobilization Outcomes in G-CSF Mobilized Patients with PB
#10 or PB. 10Median (range) cumulative CD341 cells/
kg x 106 after 2 apheresis days0.97 (0.06 - 9.16) 3.30 (0.46 - 12.00)Median (range) cumulative CD341 cells/
kg x 106 after 4 apheresis days1.31 (0.06 - 10.58) 4.52 (0.46 - 15.00)% Pts achieving $2 x 106 CD341Cells/
Kg in 2 days22.7 65.3% Pts achieving $2 x 106 CD341Cells/
Kg in 4 days34.7 79.6% Pts achieving $5 x 106 CD341Cells/
Kg in 2 days5.3 30.6% Pts achieving $5 x 106 CD341Cells/
Kg in 4 days10.7 40.8116
ADDITION OF BORTEZEMIB TO HIGH DOSE MELPHALAN DOES NOT IM-
PROVE RESPONSE RATE OR PROGRESSION-FREE SURVIVAL
Sharma, M., Qazilbash, M.H., Hosing, C.M., Thall, P.F.,
Mendoza, F.L., Han, E., Wang, M., Shah, J., Alousi, A.M.,
Anderlini, P., Kebriaei, P., Khouri, I.F., Popat, U.R., de Lima, M.,
Champlin, R.E., Giralt, S.A. M.D. Anderson Cancer Center, Houston,
TX
Background: High dose melphalan remains the preparative regi-
men of choice for autologous hematopoietic stem cell transplan-
tation (auto HCT) in multiple myeloma (MM). Bortezomib is
an active agent in newly diagnosed or relapsed MM, and has syn-
ergistic activity with melphalan. We recently conducted two ran-
domized phase II trials in MM, one of which studied the safety
and efficacy of adding bortezomib to high-dose melphalan in
the preparative regimen for auto HCT. Here we report the re-
sponse rates, progression-free survival (PFS) and overall survival
(OS) between the melphalan-based preparative regimens with or
without bortezomib.
Methods: In the first randomized trial 48 patients received high-
dose Melphalan at 100 mg/m2 IV on days -4 and -3, and ascorbic
acid (AA) 1000 mg IV daily on days -9 to -3. Patients in arm 1
did not receive arsenic trioxide (ATO); patients in arm 2 received
ATO 0.15 mg/kg IV from days -9 to -3; patients in arm 3 re-
ceived ATO at 0.25 mg/kg from days -9 to -3. In the second ran-
domized trial 60 patients were enrolled and 58 received an auto
HCT with a preparative regimen of melphalan 100 mg/m2 IV on
days -4 and -3, AA 1000 mg/day IV on days -9 to -3 and ATO
0.25 mg/kg IV on days -9 to -3. Patients in the second trial were
randomized to 3 arms; no bortezomib (arm 1), bortezomib 1 mg/
m2 on days -9, -6 and -3 (arm 2), and bortezomib 1.5 mg/m2 on
days -9, -6 and -3 (arm 3).
Results: A total of 106 patients received an auto HCT in these 2
trials. Of 106 patients, 39 received a preparative regimen with
bortezomib (Group A) and 67 without bortezomib (Group B). Pa-
tient characteristics and outcome are summarized in Table 1. Pa-
tients in group B (without bortezomib) were slightly older, had
a longer interval between diagnosis and auto HCT and 21%
had a prior auto HCT (vs. 2% in group A). Complete + very
good partial response rates (CR + VGPR) in groups A and B
were similar (31% vs. 31%). Median PFS and OS in group A
vs. B were 14 vs. 23 months (p5 0.08) and 80 vs. 82 months
(p5 0.17), respectively.
Conclusions: In this analysis of 106 patients, adding bortezomib to
a HD melphalan preparative regimen did not improve the response
rate, PFS or OS.
Patient Characteristics and Outcomes
Group A Group B
(Bortezomib) (No Bortezomib)Number of patients 39 67
Median age 59 55
Abnormal cytogenetics 13 11
Relapsed disease 10 25
Prior auto HCT 1 14
Months from diagnosis to auto HCT 9 14
Median CD34 dose 106/kg 3.9 4.56
Median days to engraftment 10 10
Grade 3-4 adverse effects 12 20
CR 7 (18%) 16 (24%)(Continued )
